Vactosertib with chemo and radiation for esophageal cancer
This trial tests whether adding a new drug called vactosertib to standard chemotherapy and radiation before surgery can help treat esophageal adenocarcinoma. It aims to see if the combination is safe and effective for patients with stage II or III disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with grade 3 adenocarcinoma of the esophagus or where it meets the stomach.
- Your cancer is stage II or III and you are scheduled to receive chemotherapy and radiation before surgery.
- You have not had chemotherapy, immunotherapy, or radiation for this cancer before.
- You are 18 years or older and able to swallow oral medication.
- You have adequate organ function, including normal liver and kidney tests, and blood counts within acceptable ranges.
- You are willing to undergo endoscopic biopsy and PET/CT scans as part of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given together with radiation therapy, followed by additional chemotherapy, for newly diagnosed adenocarcinoma (a type of cancer) in the esophagus or where the esophagus meets the stomach. The goal is to shrink the tumor and improve survival.
This trial tests a shorter course of radiation combined with chemotherapy (FOLFOX) before surgery for esophageal or stomach-junction cancer. It aims to reduce side effects and still improve outcomes.
This trial tests a treatment given before surgery for patients with a type of esophageal cancer called squamous cell carcinoma, stages II to IVA. The goal is to see if this approach can improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
Hear when a new Siewert Type II Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.